ClinicalTrials.gg
CompletedNCT02481817NoAAC PR-02Updated Oct 28, 2021

Treatment Alternatives in iSGS (NoAAC PR-02 Study)

An observational study in Idiopathic Subglottic Stenosis (iSGS), sponsored by Vanderbilt University Medical Center. Completed at 42 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-28.

Sponsored by Vanderbilt University Medical Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,239
Ages
18 Years and older
Sex
All
01

Study summary

The study is aimed at answering the questions; (1) How well do the most commonly used treatments in iSGS work? and (2) What quality-of-life trade-offs are associated with each approach?

With the results of this trial, the investigators hope to provide information to iSGS patients: (1) Given my personal characteristics, conditions, and preferences, what should I expect will happen to me? and (2) What are my options, and what are the potential benefits and harms of these options?

Read the detailed description

Idiopathic subglottic stenosis (iSGS) is a rare disease in which the trachea narrows for no known reason. Although uncommon (with an estimated incidence of 1:400,000 persons per year), both the disease and its therapies profoundly affect patients' ability to breathe, communicate and swallow. Breathing difficulties (i.e. dyspnea) is the hallmark symptom and the primary cause of death and disability. However, patients can also experience debilitating voice changes and swallowing problems due to the condition or its treatment.

People with this disease often require several surgeries per year. A variety of treatments have been advanced to manage iSGS but are generally categorized into: 1) endoscopic dilation of the tracheal stenosis (accomplished with rigid instruments or inflatable balloons); 2) endoscopic resection of the stenosis (with prolonged medical therapy after surgery); or 3) open neck surgery with resection of the affected tracheal segment with end-to-end anastomosis. Each patient can require repeated surgeries to keep their trachea open, which increases odds of treatment side effects and complications. All approaches have unique and often disabling associated side effects, which can significantly affect a patient's quality of life.

Because the disease is rare, it is difficult for patients to find good information so that they can understand the spectrum of treatment options. This is particularly difficult because most patients present with severe breathing trouble and need treatment quickly, limiting their ability to explore options. Additionally, there is a general lack of high-quality, reliable, and accessible data to inform individual patient decision-making. Imperfect information and limited evidence on treatment outcomes complicate patient decision-making as they try to balance survival, symptoms, and quality of life considerations.

Beyond the gaps in understanding the relative effectiveness of the different treatments available, no studies have explored functional outcomes in iSGS (i.e. how well patients breathe, speak, and swallow after treatments). These endpoints are important to patients and are arguably a primary determinant in decision-making. Direct engagement with patients is critical to understand these quality of life considerations, since patient and physician perspectives aren't always the same. For example, results show that endoscopic dilation is associated with a higher rate of disease recurrence and thus need for repeated surgery. Meanwhile, open tracheal resection is a major surgery with significant immediate perioperative risks and has been associated with alterations in voice and swallowing. Open tracheal resection appears to reduce the risk of disease recurrence, but the degree of benefit, and the trade-offs associated with this approach are unanswered questions.

The proposed study from the North American Airway Collaborative (NoAAC PR- 02) is designed to fill this void. Our prospective study will directly compare the effectiveness of standard of care treatments and assess their associated quality of life tradeoffs in iSGS patients.

02

Conditions studied

  • Idiopathic Subglottic Stenosis (iSGS)
03

In context

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All clinically confirmed iSGS patients at the participating institutions are eligible for enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Greater than 18 years of age.
  • The lesion must involve the subglottis.

Exclusion criteria

Exclusion Criteria:

  • Less than 18 years of age
  • Patients without capacity to consent for themselves
  • History of significant laryngotracheal traumatic injury.
  • History of endotracheal intubation or tracheotomy within 2 years of presentation.
  • Major anterior neck surgery.
  • History of neck irradiation.
  • History of caustic or thermal injuries to the laryngotracheal complex.
  • History of a clinically diagnosed vasculitis or collage vascular disease.
  • Positive antinuclear cytoplasmic antibody titers.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,239 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • iSGS patients

    Participants will receive standard of care treatment at the respective center and will be followed longitudinally for symptom changes, need for further treatment, complications, and will have Patient-reported outcomes (PROs) administered at a priori determined intervals.

    Procedure: Endoscopic dilation of subglottic stenosis · Procedure: Endoscopic resection of the stenosis · Procedure: Tracheal Resection

Interventions

  • ProcedureEndoscopic dilation of subglottic stenosis

    This is accomplished with rigid instruments or inflatable balloons.

  • ProcedureEndoscopic resection of the stenosis

    This is accomplished with C02 lasers and paired with prolonged medical therapy after surgery.

  • ProcedureTracheal Resection

    Resection of the affected tracheal segment with end-to-end anastomosis

    Also known as: Cricotracheal Resection, Open Airway Surgery

06

What researchers measure

Primary outcomes

  1. Treatment Effectiveness: Time to recurrent procedure

    Time frame: 3 years

  2. Treatment Effectiveness: Need for tracheostomy

    Time frame: 3 years

Secondary outcomes

  1. QOL

    Patient quality of life assessment: voice (VHI-10)

    Time frame: 3 years

  2. QOL

    Patient quality of life assessment: dysphagia (EAT-10)

    Time frame: 3 years

  3. QOL

    Patient quality of life assessment: breathing (COPD dyspnea)

    Time frame: 3 years

  4. QOL

    Patient quality of life assessment: general quality of life (SF-12)

    Time frame: 3 years

  5. Patient Reported Outcome

    Non-traditional PRO focused on social support

    Time frame: 3 years

  6. Patient Reported Outcome

    Non-traditional PRO focused on fear of disease recurrence

    Time frame: 3 years

  7. Patient Reported Outcome

    Non-traditional PRO focused on disease anxiety and burden

    Time frame: 3 years

  8. Patient Reported Outcome

    Non-traditional PRO focused on participatory decision-making style

    Time frame: 3 years

07

Study locations

42 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Mayo Clinic
    Scottsdale, Arizona 85054, United States
  • University of California Irvine
    Irvine, California 92606, United States
  • Loma Linda University Health Care
    Loma Linda, California 92354, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • University of California San Diego
    San Diego, California 92103, United States
  • University of California San Francisco
    San Francisco, California 94115, United States
  • University of Colorado
    Denver, Colorado 80045, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Bastian Voice Institute
    Downers Grove, Illinois 60515, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Louisiana State University
    Baton Rouge, Louisiana 70809, United States
  • Johns Hopkins
    Baltimore, Maryland 21287, United States
  • Harvard Medical School -Massachusetts Eye and Ear Infirmary
    Boston, Massachusetts 02114, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • University of Nebraska
    Omaha, Nebraska 68198, United States
  • New York University Medical Center
    New York, New York 10016, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • University of Cincinatti
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43212, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Temple University
    Philadelphia, Pennsylvania 19140, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • University of Virginia
    Charlottesville, Virginia 22908-0713, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • University of Sydney
    St Leonards, Australia
  • Landspitali University Hospital
    Reykjavik, 101-155, Iceland
  • Charing Cross Hospital, Imperial College London
    London, W6 8RF, United Kingdom
08

References and documents

Publications

  • Gelbard A, Shyr Y, Berry L, Hillel AT, Ekbom DC, Edell ES, Kasperbauer JL, Lott DG, Donovan DT, Garrett CG, Sandhu G, Daniero JJ, Netterville JL, Schindler JS, Smith ME, Bryson PC, Lorenz RR, Francis DO. Treatment options in idiopathic subglottic stenosis: protocol for a prospective international multicentre pragmatic trial. BMJ Open. 2018 Apr 10;8(4):e022243. doi: 10.1136/bmjopen-2018-022243. PubMed 29643170 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Sep 2020, 60 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2015
First posted
Jun 25, 2015
StartActual
Aug 28, 2015
Primary completionActual
Sep 10, 2020
CompletionActual
Sep 10, 2020
Last update
Oct 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02481817
Responsible party
Alexander Gelbard, MD (Assistant Professor, Department of Otolaryngology, Vanderbilt University Medical Center) — Principal investigator
First posted
Jun 25, 2015
Start date
Aug 28, 2015
Primary completion
Sep 10, 2020
Completion
Sep 10, 2020
Last update
Oct 28, 2021

Study contacts

Alexander Gelbard, MD
principal investigator · Vanderbilt University Medical Center
David O. Francis, MD, MS
study chair · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion